Is anthrax becoming an obsolete weapon? Biotechnology has changed the face of medical research. In developing defenses against anthrax, advances in genomics and proteonomics have suggested new approaches. Perhaps the days of weaponized anthrax are numbered. Join Dr. Nicholas Bergman as he discusses the United States' research emphasis on defending against an antrax attack--even against genetically engineered anthrax. Dr. Bergman received his PhD in biochemistry and molecular biology at the Massachusetts Institute of Technology. He is currently an Assistant Professor in the School of Biology at the Georgia Institute of Technology in Atlanta. He has published a paper examining some of the genomic properties of Anthrax in the Journal of Bacteriology.
The Future of Anthrax Research and Defense
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Is anthrax becoming an obsolete weapon? Biotechnology has changed the face of medical research. In developing defenses against anthrax, advances in genomics and proteonomics have suggested new approaches. Perhaps the days of weaponized anthrax are numbered. Join Dr. Nicholas Bergman as he discusses the United States' research emphasis on defending against an antrax attack--even against genetically engineered anthrax. Dr. Bergman received his PhD in biochemistry and molecular biology at the Massachusetts Institute of Technology. He is currently an Assistant Professor in the School of Biology at the Georgia Institute of Technology in Atlanta. He has published a paper examining some of the genomic properties of Anthrax in the Journal of Bacteriology.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Level Up Your Skills: Tailoring Management of HF
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?